Paratek Pharmaceuticals, Inc.: management transactions · United States · SEC (Form 4)

About Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc. is a U.S.-listed biopharmaceutical company traded on NASDAQ in the United States. For French, Belgian, and Swiss investors, it fits the profile of a specialty healthcare company focused on infectious diseases, antimicrobial resistance (AMR), and selected high-unmet-need therapeutic niches. The company positions itself as a developer and commercializer of specialty medicines aimed at adult patients and clinicians in both hospital and outpatient settings. Paratek’s corporate story is rooted in the U.S. specialty biotech ecosystem and in research tied to tetracycline science and hard-to-treat infections. The company has built its commercial identity around NUZYRA® (omadacycline), an FDA-approved tetracycline-class antibiotic used for certain acute bacterial infections in adults, and more recently around XHANCE®, a prescription nasal spray approved in the United States for chronic rhinosinusitis with or without nasal polyps in adults. That gives Paratek two distinct commercial pillars: anti-infectives on one side, and ENT/inflammatory care on the other. From a competitive standpoint, Paratek is best viewed as a focused specialty pharma company rather than a diversified large-cap drug maker. Its edge comes from clinical expertise, targeted positioning in underserved indications, and a commercial model built around specific physician and patient populations. The company also emphasizes its role in addressing AMR, which it describes as a major public health and national security issue in the United States. In addition, Paratek has highlighted work related to potential biodefense applications for NUZYRA, reflecting a broader strategic interest beyond routine community infections. Geographically, Paratek remains primarily U.S.-centered. Its corporate footprint includes King of Prussia, Pennsylvania, and Boston, Massachusetts, underscoring a domestic operating structure tied to FDA regulation, U.S. reimbursement dynamics, and American prescribing behavior. For investors, that means the company’s performance is closely linked to U.S. market access, promotional execution, and the adoption curve of its branded products. Recent developments highlighted by the company include continued focus on expanding the impact of XHANCE in chronic rhinosinusitis and sustaining NUZYRA’s role in the treatment of bacterial infections and the AMR narrative. Because the company is followed through SEC Form 4 insider transaction filings, capital-market observers also pay attention to insider buying and selling patterns, which can be relevant for a mid-cap NASDAQ-listed specialty pharma name with a product-led growth story.